NPPA gets Delhi HC notice on AstraZeneca plea over cancer drug Tagrisso
New Delhi: The Delhi High Court on Monday issued notice to National Pharmaceutical Pricing Authority (NPPA) and others on AstraZeneca Pharma India's petition challenging notice relating to Tagrisso 80 mg tablets.A Division Bench of Justices DN Patel and Jyoti Singh asked NPPA and others to file their replies to the petition filed by AstraZeneca Pharma and listed the matter for August 20,...
Login or Register to read the full article
New Delhi: The Delhi High Court on Monday issued notice to National Pharmaceutical Pricing Authority (NPPA) and others on AstraZeneca Pharma India's petition challenging notice relating to Tagrisso 80 mg tablets.
A Division Bench of Justices DN Patel and Jyoti Singh asked NPPA and others to file their replies to the petition filed by AstraZeneca Pharma and listed the matter for August 20, reports ANI.
AstraZeneca Pharma has sought quashing of the demand notice issued by NPPA for an amount of Rs 157 crores.
The NPPA had issued a notice alleging that the company has overcharged about Rs 157.38 crores during the period from March 8, 2019, to January 31, 2021, in respect of Tagrisso (Osimertinib) 80 mg tablets.
Medical Dialogues team had earlier reported that AstraZeneca had claimed that it has a product patent covering the molecule OSIMERTINIB (TAGRISSO) and the same is valid for twenty years, i.e. up to 24.07.2032, making the Show Cause Notice dated 14.10.2020 and the impugned order dated 13.01.2021 issued by NPPA thus illegal and to be quashed.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd